SMAD5 and pulmonary arterial hypertension: SMAD5 levels were similarly reduced in patients with PAH with and without pathogenic BMPR2 variants (Figure E7A), supporting the observation that impaired signaling in the BMPR2 pathway is more common in PAH than rare mutations in BMPR2 suggest.